1. Agur Z, Arnon R, Schechter B (1988) Reduction of cytotoxicity to normal tissues by new regimes of phase-specific drugs. Math Biosci 9:1–15
2. Andaloussi AE, Lesniak MS (2006) An increase in CD4+ CD25 FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neurooncol 8:234–243
3. Arakelyan L, Merbl Y, Agur Z (2005) Vessel maturation effects on tumor growth: validation of a computer model in implanted human ovarian carcinoma spheroids. Eur J Cancer 41:159–167
4. Arciero JC, Jackson TL, Kirschner DE (2004) A mathematical model of tumor-immune evasion and siRNA treatment. Discret Contin Dyn S B 4:39–58
5. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143:3222–3229